Featured

Fundraising success for the RSPCA as Dogust draws to a close

As GLOBALHealthPR (GHPR) initiative #Dogust draws to conclusion, VIVA! Communications is celebrating the roaring success of our recent fundraising bake sale for the RSPCA. Generating more than $170 through in-person donations alone, VIVA! raised the dough this year by 34 per cent in comparison to the same event last year. Celebrating ‘Cupcake Day’, an annual…

Read More

Cochrane review pours cold water on heart protective benefits of fish oil

A recently published Cochrane review has poured cold water on the value of smelly fish oil preparations. Despite long being touted as a “miracle food” for their alleged cardio-protective benefits, Australia’s most commonly taken supplement does nothing to reduce cardiovascular events, coronary heart deaths, stroke or even heart irregularities. The analysis examined evidence from almost…

Read More

The science & prescribing of medicinal cannabis

Three leading integrative medicine bodies will unite in Sydney next month (September 8 – 9) to educate Australian practitioners on the science and prescribing of medicinal cannabis. The 2-day-long, RACGP accredited event will focus on clinical applications, patient safety and local regulations for the prescribing of medicinal cannabis. According to event organisers – the National…

Read More

Simple blood test to detect early stage melanoma on horizon

Aussie researchers have developed the world’s first blood test to detect early stage melanoma. Researchers from Edith Cowan University (ECU), Perth produced the test after examining more than 1,600 functional proteins and identifying 10 auto-antibodies associated with melanoma. Early detection of melanoma is associated with an 80 – 95% survival rate. The blood test, which…

Read More

Seqirus to release additional 700,000 adult flu vaccine doses to help boost “community immunity” against preventable infection

Seqirus announced the manufacture of another 500,000 doses of their adult influenza vaccine, Afluria Quad (inactivated quadrivalent influenza vaccine, split virion) today to help meet increasing consumer demand. Having fulfilled the government’s request to re-enter production, Seqirus is now ahead of the National Immunisation Program (NIP) schedule, with its first vaccine set for release this…

Read More